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Pharmacokinetics of FK506 in Liver 
Transplant Recipients After Continuous 
Intravenous Infusion 
Ashok B. Jain, MD, Kareem Abu-Elmagd, MD, Hisham Abdallah, PhD, Vijay Warty, PhD, 
John Fung, MD, PhD, Satoru Todo, MD, Thomas E. Starzl. MD, PhD, 
and Raman Venkataramanan, PhD 
The fIrst·dose pharmacokinetics of FK506 was studied in nine orthotopic liver transplant 
patients receiving continuous intravenous infusion of O.lS mg/kg/dav. lvlultiple blood 
samples were obtained during the infusion and plasma FK506 concentrations were mea-
sured by enzyme-linked immunosorbent assay. The plasma clearance ranged from 0.47 
to 5.B L/minute, and the half-life ranged from 4.5 hours to 33.1 hours. These results 
indicate the pharmacokinetics of FK506 to be highly variable between patients. FKS06 is 
extensively distributed outside the plasma compartment. FK506 is extensively metabo-
lized in the body, with less than 1 %) of the administered dose being excreted in the urine 
as unchanged FK506. The large variability in FKS06 kinetics during the immediate post· 
operative period is attributed to the variability in the functional status of the liver in the 
transplant patients. Because of the long half-life of FKS06, it takes more than 45 hours to 
reach steady-state concentrations after continuous infusion. Based on the estimated ki-
netic parameters, it appears that a combination of a bolus or a rapid infusion of .02 
mg/kg with a continuous infusion of o.os mg/kg/day will provide and maintain a con-
centration of more than 2 ng/mL from the beginning of the drug treatment. 
FK506 is a macrolide isolated from the fungus Streptomyces tsukubaensis. 1 It is nearly 100 times 
more potent than cyclosporine (CsA) in inhibiting 
lymphocyte proliferation in mixed lymphocyte cul-
tures. 2 FKS06 has been shown to prevent or reverse 
the rejection of heart. liver, kidney. pancreas. lung, 
intestine, and skin grafts in mice. rats. dogs. mon-
keys, and baboons. 3 FKS06 has been in clinical use 
since March 1989 at the University of Pittsburgh. It 
was used initially for rescuing livers that have failed 
under conventional immunosuppression and later as 
the primary immunosuppressant for liver, kidney, 
and heart transplantation. 4- 6 Current results indicate 
that FKS06 provides better immunosuppression in 
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liver and heart transplant recipients than does 
CsA.4 ,6-8 
After transplantation, FK506 is administered intra-
venously as a continuous infusion at a dose of 0.15 
mg/kg/day and then orally at a dose of 0.3 mg/kg/ 
day twice daily, when the patient can tolerate oral 
intake. Further dose alterations are normally made 
based on patient's liver function, episodes o'f rejec-
tion or toxicity, and trough plasma FK506 concentra-
tions. The intravenous dosage form of FK506 is a 10-
mg/mL FKS08 solution with polyethoxylated hydro-
genated castor oil (HCO-60, a nonionic surfactant) 
and alcohol. This solution is diluted in 100 mL of 5% 
dextrose and infused at a rate of 4 mL/hour O\'er 24 
hours. The pharmacokinetics of FKS06 has been pre-
viously studied in liver transplant patients who re-
ceived their daily dose as a 2- or 4-hour infusion.g-ll 
The purpose of the curren t study was to characterize 
the pharmacokinetics of FKS06 in orthotopic liver 
transplant recipients receiving continuous intrave-
nous administration of FKS06 during the immediate 
postoperative period and to compare actual steady-
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state FK506 concentrations with concentrations pre-
dicted based on the 24-hour kinetic study. 
MATERIALS AND METHODS 
Patients 
Nine consecutive adult patients (8 men and 1 
woman) who had undergone orthotopic liver trans-
plantation received a continuous intravenous infu-
sion ofFK506 (0.15 mg/kg/day) as their primary im-
munosuppressant 2 to 4 hours after surgery. FK506 
was administered as a continuous intravenous infu-
sion for a minimum of 3 to 6 days. They also received 
20 mg of methyl prednisone during the first 24 hours. 
Patients' ages ranged from 24 to 64 years. and the 
patients weighed between 40 and 114 kg, with a 
mean of 71 kg. Written informed consents were ob-
tained from all patients. and the study protocol was 
approved by the University of Pittsburgh Institu-
tional Review Board for Biomedical Studies. 
Specimen Collection 
Multiple blood samples (3 mL) were drawn at 0, 15, 
30,45 minutes, 1. 2, 3, 4, 5, 6. 8. 12, 16, and 24 hours 
after starting FK506 infusion from arterial lines into 
heparinized vacutainers. Blood samples were incu-
bated at 37°C for 30 minutes. and plasma was sepa-
rated by centrifugation at 37°C and frozen at -70oe 
until analysis. Twenty-four-hour urine collections 
also were made, and aliquots of the samples were 
frozen for FK506 analysis. 
Assay 
FKs06 concentration in plasma separated at 37°e 
was measured by a monoclonal-antibody-based en-
zy-me-linked immunosorbent assay.1213-The coeffi-
cIent of variation of this assay is 19.8% at 0.4 ng/mL, 
14% at 1.6 ng/mL. and 16% at 2.6 ng/mL. 
Data Analysis 
chR~S concentration-time data were analyzed by 
nonlInear curve fitting with MINSQ program 
(MINSQ. 1987) using a two-compartment model. 
cp = A· (1 - exp[Laml . t]. [K21 - Laml] 
X exp[ -Laml . tll[ -Laml . [Lam2 - Lam1]) 
+ A· (1 - exp[Lam2 . t] . [K21 - Lam2] 
X exp[-Lam2·t]/[-Lam2·[Lam1 - Lam2]) 
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where Lam1 and Lam2 are the two exponents and 
the rest are as described by standard methods.14 
Using the parameter estimates obtained from fit-
ting the data (A. C. Lam1. Lam2. K21 .) kinetic parame-
ters (half-life. cleiuance. volume of distribution. and 
steady state plasma concentration Css) were calcu-
lated according to standard techniques. 14 In addition, 
the steady-state concentration that will be achieved 
on the infusion regimen was predicted for each pa-
tient based on the kinetic parameters (clearance) cal-
culated from 24-hour plasma concentration-time 
data and the infusion rate (Css = infusion rate/clear-
ance) and compared with the actual steady-state 
concentrations measured 3 to 6 days after the ~tart of 
the infusion. -
RESULTS 
The characteristics of the patients who participated 
III the present study are summarized in Table I. The 
bilirubin and serum glutamic oxaloacetic transami-
nase and serum glutamic-pyruvic transaminase con-
centra.tions varied widely in these patients. A repre-
sentatIve plasma concentration-time profile of 
FK506 in two patients (one with the lowest and one 
with the highest bilirubin) during continuous intra-
venous infusion is shown in Figure 1. Table II sum-
marizes the pharmacokinetic parameters of FK506 in 
each of the patients studied. The total body clear-
ance of FK506 is estimated to be 1.76 ± 1.75-L/min. 
The initial and terminal disposition rate constants 
are 1.23 ± 1.08/hour and .071 ± .05/hour, respec-
tively. The mean disposition half-life is 15.5 hours. 
The steady-state volume of distribution. Vss ' is 1252 
± 668 L. 
Based on the pharmacokinetic par~meters calcu-
lated in each patient. the steady-state concentration 
that will be reached eventuallY"in these patients was 
calculated according to the following equation: 
Steady state concentration = Infusion rate / Cal-
culated Clearance 
Table III summarizes the biochemical profile and 
observed and predicted FK506 plasma concentra-
tions on the last day of intravenous therapy. Reason-
able agreement (less than 30% difference) was ob-
served between the calculated and the actual C on 
days 3 to 6 in patients 4, 6,7, and 8. In patients Os~nd 
5, where the liver function improved based on biliru-
bin concentrations, the actual steady-state concen-
tration on day 4 was less than what was predicted 
based on the first 24-hour kinetics. In patients 1 and 
3. the predicted steady-state levels were lower than 
actual Cos reached on days 4 or 3, respectively. Dur-
ing this period, bilirubin concentrations increased in 
patient 3, indicating deterioration of liver function. 
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TABLE I 
Biochemical Profiles in Patients· 
Age B.W. Bilirubin 
Patient # yr kg mg/dL 
1 37 75 5.5 
2 61 70 3.8 
3 47 114 11.5 
4 24 49 2.8 
5 64 40 3.6 
6 25 51 9.1 
7 36 78 2.0 
8 60 88 2.5 
9 25 77 4.8 
• All biochemical parameters were measured on study date. 
but decreased in patient 1. There was no significant 
correlation V= .248) between the plasma clearance 
of FK506 and the serum bilirubin concentrations on 
day 1. The observed FK506 concentrations on days 3 
to 6 also did not correlate well (r = 0.473; P = .234) 
with the total bilirubin concentrations on the corre-
sponding days. Less than 1 % of the administered 
dose was recovered in the urine as FK506 over a 24-
hour period. 
DISCUSSION 
Since the introduction of CsA, the discovery of 
FK506 is the most important step in the advance-
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Figure 1. Plasma concentration versus time curve after continuous 
intravenous infusion of FK 506 in patient 6 with the highest serum 
bilirubin and patient 2 with the lowest serum bilirubin concentra· 
tions. 
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SGP1 SG01 SCR BUN 
U/L UL mg/dL mg/dL 
893 1198 0.8 16 
2244 2685 0.5 9 
463 280 0.7 20 
413 666 0.6 7 
593 753 0.5 11 
3100 4331 2.8 46 
319 422 0.6 14 
365 357 1.8 40 
960 903 0.6 17 
ment of immunosuppressive therapy for organ trans-
plant patients. FK506 is a macrolide and is very dif-
ferent in its chemical structure from any other immu-
nosuppressive drug used currently. In this study, we 
examined the plasma concentration-time profile in 
nine consecutive orthotopic liver transplant patients 
receiving a continuous infusion of FK506 as their 
primary immunosuppressant. The assay method 
that was used to measure FK506 in plasma is a sensi-
tive monoclonal antibody-based enzyme immunoas-
say. Because metabolites of FK506 have not been 
completely characterized, it was not possible to de-
termine the potential cross-reactivity of any FK506 
metabolites with the antibody used in this assay. Pre-
liminary studies, however, indicate that a fraction 
collected in HPLC (presumably a metabolite of 
FK506) does cross-react with the antibody used in 
the FK506 analysis (unpublished observation). In the 
absence of FK506 concentration measurement using 
a completely specific assay, the results of this study 
have to be interpreted with caution. The partitioning 
of FK506 between blood cells and plasma is tempera-
ture dependent. 15 To be physiologically meaningful. 
blood was separated at 37°C in this study . 
The overall beha vior of the drug in the body could 
be adequately described by a biexponential equa-
tion. The plasma concentrations attained in 24 hours 
with the infusion rate ofO.l5 mg/kg/day ranged be-
tween 2 and 7 ng/mL. The mean plasma clearance of 
FK506 was 1.76 L/minute and was variable between 
patients. Based on these data, one would classify 
FK506 as a high-clearance drug if the blood concen-
tration of the drug were to be similar to the plasma 
concentration. Recent evidence, however, suggests 
that the drug is extensively distributed into red 
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TABLE II 
Pharmacokinetic Parameters of FK 506 
Distribution Disposition 
Rate Constant Rate Constant 
Patient # (hr- 1 ) (hr- 1) 
1 0.469 0.0975 
2 0.453 0.0939 
3 0.469 0.0889 
4 0.770 0.0276 
5 0.521 0.0439 
6 3.10 0.0210 
7 2.61 0.0225 
8 0.456 0.0878 
9 2.18 0.1555 
Mean ± SD 1.23 ± 1.08 0.0710 
0.05 
blood cells. with a blood-to-plasma ratio of nearly 
12.15 This indicates that the clearance calculated 
from the blood data will be considerably small and 
the drug is actually a low clearance drug. In addition, 
it is possible that FK506 also may be metabolized 
extrahepatically; there is evidence of FK506 metabo-
lism in rat small intestine. I6 
There was a large variation in FK506 clearance be-
tween patients. The differences in the functional sta-
tus of the liver between patients is expected to have 
contributed to the observed variation in the clear-
ance of FK506. Factors such as cold ischemic dam-
Volume of 
Disposition Distribution 
Half-Life at Steady State Clearance 
(hr) (L) (Ljmin) 
7.1 822 l.56 
7.4 406 0.62 
7.8 1355 3.38 
25.1 1857 l.06 
15.8 573 0.47 
33.1 960 0.36 
30.7 2441 l.oo 
7.9 1058 1.63 
4.5 1796 5.75 
15.5± 11.2 1252 ± 668 1.76 ± 1.75 
age. reperfusion injury. and accumulated endoge-
nous inhibitors of drug metabolism also may have 
contributed to the observed variation in the clear-
ance of FK506 during the immediate postoperative 
period. Lack of correlation between bilirubin levels 
and FK506 concentrations may be related to the fact 
that bilirubin concentrations may not reflect the 
functional status of the liver during the immediate 
postoperative period. The highest half-life and the 
smallest clearance values, however. were observed 
in a patient who had the highest serum bilirubin 
concentrations (>9 mg/ dL) during the entire first 
TABLE III 
Biochemical Profiles in Patients* 
Last Day Plasma FK 506 
on IV Bilirubin SGPT SGOT SCr BUN Concentration (ngjmL) 
Patient # Therapy mgjdL UjL UL mg/dL mgjdL Observed Predicted 
1 4 2.4 555 134 1.0 38 11.0 5.1 
2 5 0.9 609 95 0.8 24 7.5 10.7 
3 3 13.9 383 185 0.9 65 7.3 3.2 
4 3 0.6 168 112 0.6 9 5.1 5.0 
5 6 1.7 204 66 1.2 14 4.5 8.4 
6 6 11.3 122 72 3.4 72 14.4 12.9 
7 3 0.9 475 354 2.0 32 7.0 8.0 
8 3 1.5 229 134 3.7 73 8.4 6.1 
9 4 4.8 294 52 1.1 31 -t 1.5 
• Parameters estimated on last day of IV therapy. t Not available 
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week after transplantation. Conversely. accumula-
tion of FKS06 metabolites in patients with poor liver 
function and the inability of the assay to distinguish 
between unchanged FKS06 and some of its metabo-
lites could presumably explain the lack of correla-
tion between serum bilirubin concentration and 
FK506 clearance. 
Analysis of the 12-hour trough concentrations of 
FK506 in a large group of patients (n = 49) with dif-
ferent qualities of liver graft function indicates high 
trough FKS06 concentrations in patients with poorly 
functioning grafts. 17 There also was a significant posi-
tive correlation between serum bilirubin and trough 
FKS06 plasma concentrations despite a negative 
correlation between serum bilirubin and FK506 
doses in these patients. It also has been shown that in 
patients with poor liver function. as indicated by bili-
rubin concentrations, the 24-hour trough concentra-
tions after two or four infusions of FK506 (0.15 mg/ 
kg/day) are higher than those observed in patients 
with normal liver function. 11 The functional status of 
the liver doe~not remain constant during the imme-
diate postoperative period in all liver transplant pa-
tients. It is not surprising. however. that steady-state 
concentrations could not be predicted in all patients 
based on the kinetic studies performed on day 1 after 
transplant. In four patients, where the liver function 
remained satisfactory or did not change signifi-
cantly, the observed steady-state concentrations 
were within 30% of the predicted values. In two pa-
tients, where the liver function improved over the 
study period, the observed steady-state concentra-
tions were lower than predicted. In patient 3, with a 
worsening of the liver status, the observed steady-
state concentration was higher than the predicted 
value. Taken together. these observations indicate a 
dependency of FK506 concentrations on liver status 
and indicate a need for careful adjustments in FK506 
dosing in such patients. 
The large volume of distribution of FK506 suggests 
extensive distribution of the drug outside the plasma 
compartment. Recent studies have shown FK506 to 
bind preferentially tn erythrocytes with blood-to-
plasma ratios of 10 to 1 (Unpublished observation). 
Based on studies in animals,9 high concentrations of 
FK506 are expected in lungs. kidneys, heart. and 
spleen. Because of the large volume of distribution of 
FK506, the fact that FK506 is extensively metabo-
lized in the liver. and that a large amount of FK506 
remains outside the plasma compartment. for a given 
period of dialysis. a significant fraction of the body 
load of FK506 is not likely to be removed. 
The mean half-life of FK506 is 15.5 hours. This 
indicates that after continuous infusion it will take at 
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least 45 hours to reach 90% of the steady-state levels. 
After a change in the dosing regimen. one has to wait 
for a minimum of 45 hours to attain a new steady_ 
state FKS06 plasma concentration. After continuous 
infusion of FKS06 at a dosage of O.lS mg/kg/ day. on 
average it would take nearly 10 hours to reach a 
plasma concentration of 2 ng/mL. Conversely. based 
on computer simulations, after two or four infusions 
this concentration is achieved in about 1 hour, but 
with a peak plasma concentration of6.7 and S.l ng/ 
mL at the end of the corresponding infusion times. 
One approach to achieving a concentration of about 
2 ng/mL immediately after beginning of treatment 
and to maintaining it at this concentration is to use a 
small bolus dose or a rapid infusion over 1 hour of 
FKS06 (.02 mg/kg). The plasma concentration then 
can be maintained around 2 ng/mL by a continuous 
infusion at .05 mg/kg/day, started immediately .. 
The pharmacokinetic parameters calculated after 
continuous infusion of FK506 are similar to the val-
ues reported after shorter infusion. lO·11 It takes more 
than 4S hours to reach a new steady state after any 
change in the dosing regimen. It is necessary to 
closely monitor the FKS06 concentrations in pa-
tients, especially in the presence of abnormal liver 
function. 
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